Galderma Laboratories, L.P. v. Amneal Pharmaceuticals LLC


King & Spalding won Federal Circuit affirmance on behalf of Galderma Laboratories.

A federal appeals court on Wednesday partially upheld a patent ruling that blocked Amneal Pharmaceuticals LLP from launching a generic version of the Galderma Laboratories LP rosacea drug Oracea.

The U.S. Court of Appeals for the Federal Circuit affirmed in part a decision that found Amneal’s proposed generic would infringe five Galderma patents. The unanimous three-judge panel said a trial judge correctly ruled that Amneal infringed three of the five patents, but cleared the Indian generic drug company of infringing the other two.

The King & Spalding team included Gerald J. Flattmann Jr (Picture), Evan Diamond, Jeong Ku Choi, Andrew Cochran, Vanessa Yen, Jesse Snyder, Abby Parsons and Julia Kolibachuk.

Involved fees earner: Andrew Cochran – King & Spalding; Evan Diamond – King & Spalding; Gerald Flattmann Jr – King & Spalding; Julia Kolibachuk – King & Spalding; Jeong Ku Choi – King & Spalding; Abby Parsons – King & Spalding; Jesse Snyder – King & Spalding; Vanessa Yen – King & Spalding;

Law Firms: King & Spalding;

Clients: Galderma Laboratories;

Author: Ambrogio Visconti